The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-28 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
The most studied ring destructive pathway is the Kodama pathway and it was initially identified in Pseudomonas abikonensis and Pseudomonas jijani. The pathway comprises four main steps: i) the successive hydroxylation by NADH-dependent dioxygenases of the carbons in one of the aromatic rings, followed by ii) the dehydrogenation of the ring by a NAD+ cofactor and further iii) oxygenation promoting ring cleavage and formation of a pyruvyl branch; concluding with iv) the hydrolysis of the pyruvyl substituent to release pyruvate and the remaining of the substrate. Since the end products of the pathway are still water soluble sulfur compounds, the pathway has often been disregarded as an appealing pathway for industrial applications, in particular by the oil industry. The most well-studied sulfur specific pathway is the 4S pathway, first discovered in the bacterium Rhodococcus erythropolis (strain IGTS8), which was observed to remove sulfur from dibenzothiophenes and derivatives in three steps: i) a double oxidation of the sulfur (to sulfoxide and sulfone) performed by a flavin-dependent monoxygenase, followed by ii) a carbon-sulfur bond cleavage by a second flavin-dependent monoxygenase and a iii) desulfination reaction through which 2-hydroxybiphenyl and sulfite are produced.
He also places a massive £300 million long position on pound sterling, gambling that a rumored UK tax cut will raise the value of the pound. When the tax cut is realised, it has the opposite effect, putting Rishi at risk of booking millions in losses. After a disastrous casino binge, Diana agrees to cover his debts—only for Rishi’s long position to suddenly net £18 million when the tax cut is reversed alongside a significant increase in the pound interest rate. this success, however, prompts him to immediately take out another gambling loan. When Pierpoint’s stock collapses on its 150th anniversary, Rishi correctly deduces an acquisition after spotting the Barclays CEO enter the building. He interviews with Harper for a hedge fund role, only find that the job offer is a sham designed to humiliate him in front of Sweetpea and Anraj, who she has hired. On Rishi's birthday, Vinay tells Diana about Rishi’s debts and murders her in front of him, leaving Rishi traumatized. In series 4, Rishi is without a job, as he is unable to clear even basic background checks due to his wife's murder, and is revealed to have attempted suicide while living in a motel and abusing prescription drugs. Harper, who paid for his stay in rehab, gives him cash payments to surreptitiously obtain information that would aid her in shorting companies. Harper later cuts ties with Rishi after hiring Sweetpea, who is repulsed by him and refuses to work with Harper if he is involved.
The announcement of the regulations which brought down the Wall took place at an hour-long press conference led by Günter Schabowski, the outgoing party leader in East Berlin and top party spokesman as Secretary for Information, beginning at 18:00 CET on 9 November and broadcast live on East German television and radio. Schabowski was joined by Minister of Foreign Trade Gerhard Beil and Central Committee members Helga Labs and Manfred Banaschak. Topics of the press conference included the results of votes at the Central Committee meeting, the surprising removal of SED Bezirk First Secretaries Hans-Joachim Böhme and Werner Walde, the SED's electoral and press reform plans and the new travel regulations. Schabowski had not been involved in the discussions about the new regulations and had not been fully updated. Shortly before the press conference, he was handed a note from Krenz announcing the changes, but given no further instructions on how to handle the information. The text stipulated that East German citizens could apply for permission to travel abroad without having to meet the previous requirements for those trips, and also allowed for permanent migration between all border crossings—including those between East and West Berlin. At 18:53, near the end of the press conference, ANSA's Riccardo Ehrman asked if the draft travel law of 6 November was a mistake.
The court's decision protects active service members from being dismissed, but doesn't abolish the ban on recruitment. June 2 The U.S. Supreme Court allows Alabama to redistrict its congressional map for the upcoming midterm elections. The new map favors the Republican Party. Trump names businessman Bill Pulte as the acting Director of National Intelligence, replacing Tulsi Gubbard who resigned. The New York Times reports that the DOJ is investigating former U.S. Representative George Santos for insider trading on Kalshi by betting on himself that he would not show up to the 2026 State of the Union Address. The Trump administration proposes a 10% tariff on countries who failed to enforce bans on products made with forced labor. Trump suggests that the UFC Arena being built on the White House's South Lawn for the June 14th UFC Freedom 250 fights could be a permanent installation, likening it to France's decision to keep the Eiffel Tower after the 1889 Paris Exposition. June 3 The U.S. House passes a resolution by a vote of 215–208 to limit Trump's war powers and end hostilities in the Iran war with four Republicans (Tom Barrett (MI), Warren Davidson (OH), Brian Fitzpatrick (PA), and Thomas Massie (KY)) joining all Democrats. The resolution is seen as symbolic as it would need to pass the U.S. Senate and survive a presidential veto; Trump derides the defecting Republicans as "grandstanders". Senate Republicans strip $1 billion in funding for security upgrades to the proposed White House ballroom from a revised budget reconciliation bill.
Sources: en.wikipedia.org
=== Impact === Soon after the publication of Libby's 1949 paper in Science, universities around the world began establishing radiocarbon-dating laboratories, and by the end of the 1950s there were more than 20 active 14C research laboratories. It quickly became apparent that the principles of radiocarbon dating were valid, despite certain discrepancies, the causes of which then remained unknown. The development of radiocarbon dating has had a profound impact on archaeology – often described as the "radiocarbon revolution". In the words of anthropologist R. E. Taylor, "14C data made a world prehistory possible by contributing a time scale that transcends local, regional and continental boundaries". It provides more accurate dating within sites than previous methods, which usually derived either from stratigraphy or from typologies (e.g. of stone tools or pottery); it also allows comparison and synchronization of events across great distances. The advent of radiocarbon dating may even have led to better field methods in archaeology since better data recording leads to a firmer association of objects with the samples to be tested. These improved field methods were sometimes motivated by attempts to prove that a 14C date was incorrect. Taylor also suggests that the availability of definite date information freed archaeologists from the need to focus so much of their energy on determining the dates of their finds, and led to an expansion of the questions archaeologists were willing to research.
Rett syndrome and fragile X syndrome (FXS) are single gene disorders related to autism with overlapping symptoms that include deficient neurological development, impaired language and communication, difficulties in social interactions, and stereotyped hand gestures. It is not uncommon for a patient to be diagnosed with both autism and Rett syndrome or FXS. Epigenetic regulatory mechanisms play the central role in pathogenesis of these two disorders. Genomic imprinting may also contribute to the development of autism. Genomic imprinting is another example of epigenetic regulation of gene expression. In this instance, the epigenetic modification(s) causes the offspring to express the maternal copy of a gene or the paternal copy of a gene, but not both. The imprinted gene is silenced through epigenetic mechanisms. Candidate genes and susceptibility alleles for autism are identified using a combination of techniques, including genome-wide and targeted analyses of allele sharing in sib-pairs, using association studies and transmission disequilibrium testing (TDT) of functional or positional candidate genes and examination of novel and recurrent cytogenetic aberrations. Results from numerous studies have identified several genomic regions known to be subject to imprinting, candidate genes, and gene-environment interactions. Particularly, chromosomes 15q and 7q appear to be epigenetic hotspots in contributing to autism. Also, genes on the X chromosome may play an important role, as in Rett syndrome.
In order to appeal to as many demographic groups as possible and better compete with its competitor, Wendy's, Burger King added a multi-tiered value menu in 1993 with items priced at 99¢, US$1.99 and $2.99. The additions, part of the CEO James Adamson's back-to-basics program called Operation Phoenix, were an attempt to add not only a value menu, but also a line of value meals. The tiered menu was replaced with a more standard value menu in 1998 while the value meals were separated into their own menu segment. This value menu featured seven products: Whopper Jr., five-piece Chicken Tenders, a bacon cheeseburger, medium-sized French fries, medium soft drink, medium onion rings, and a small milkshake. In 2002 and 2006, BK revamped its value menu, adding and removing several different products such as chili and its Rodeo Cheeseburger. Many of these items have since been discontinued, modified or relegated to a regional menu option. To better appeal to a more adult palate and demographic, BK introduced several new products to its menu in 2003, including several new or revamped chicken products, a new salad line and its BK Joe brand of coffee. Some of the new products, including their Enormous Omelet Sandwich line and the BK Stacker line, brought negative attention due to the large portion size, and amounts of unhealthy fats and trans-fats. Many of these products featured higher quality ingredients like whole chicken breast, Angus beef, and natural cheeses such as cheddar and pepper jack. Again, not all these products, such as the BK Baguette line, have met sales expectations.
Human mitochondrial DNA encodes 13 proteins of the respiratory chain, while most of the estimated 1,500 proteins and components targeted to mitochondria are nuclear-encoded. Defects in nuclear-encoded mitochondrial genes are associated with hundreds of clinical disease phenotypes including anemia, dementia, hypertension, lymphoma, retinopathy, seizures, and neurodevelopmental disorders. A study by Yale University researchers (published in the February 12, 2004, issue of the New England Journal of Medicine) explored the role of mitochondria in insulin resistance among the offspring of patients with type 2 diabetes. Other studies have shown that the mechanism may involve the interruption of the mitochondrial signaling process in body cells (intramyocellular lipids). A study conducted at the Pennington Biomedical Research Center in Baton Rouge, Louisiana showed that this, in turn, partially disables the genes that produce mitochondria.
No new information about the album was included, but the duo gave additional thoughts on Def Jam, Lamar's verse, and hopes for the tour, along with discussion of Pusha T's activities in the fashion industry: his role as a Louis Vuitton brand ambassador, walking on the runway for Williams's show, and his appearance at the Met Gala. Clipse appeared on the New York Times' podcast Popcast on June 24. Speaking to Joe Coscarelli and Jon Caramanica, the duo went over various aspects of their history—the making of their mixtape series, Malice's reasons for quitting, the moment they realized their music was reaching a wide audience, and more, in addition to the impact of becoming parents (and, in Malice's case, a grandparent) on their music and the minor detail that "Chains & Whips" would be the second track. Pusha T explained the change in behavior from Def Jam representatives after hearing Lamar's verse and revealed the official reason they were given for the demand that the verse be removed; his issues with Drake, West, and Travis Scott were also explored. They hosted a Ask Me Anything session on the subreddit r/hiphopheads on July 15.
Sources: en.wikipedia.org
=== 90Sr === Strontium-90 has been used by the Soviet Union in terrestrial RTGs. 90Sr decays by β− decay into 90Y, which quickly β-decays again. It has a lower decay energy than 238Pu, but its shorter half-life of 28.8 years and lower atomic weight yield a power density for pure metal of 0.95 watts per gram. As 90Sr is a very reactive alkaline earth metal and a bone seeker that accumulates in bone-tissue due to its chemical similarity to calcium (once in the bones it can significantly damage the bone marrow, a rapidly dividing tissue), it is usually not used in pure form in RTGs. The most common form is the perovskite strontium titanate (SrTiO3) which is chemically nigh-inert and has a high melting point. While its Mohs hardness of 5.5 has made it ill-suited as a diamond simulant, it is of sufficient hardness to withstand some forms of accidental release from its shielding without too fine dispersal of dust. The downside to using SrTiO3 instead of the native metal is it reduces power density, as the TiO3 part of the material does not produce any decay heat. 90Sr has a high fission product yield in the fission of both 235U and 239Pu and is thus available in large quantities at a relatively low price if extracted from spent nuclear fuel. Starting from the oxide or the native metal, one pathway to obtaining SrTiO3 is to let it transform to strontium hydroxide in aqueous solution, which absorbs carbon dioxide from air to become less soluble strontium carbonate.
The optimal ranges for estrogen apply only to individuals taking estradiol (or an ester of estradiol), and not to those taking synthetic or other non-bioidentical preparations (e.g., conjugated estrogens or ethinylestradiol). Physicians also recommend broader medical monitoring, including complete blood counts; tests of renal function, liver function, and lipid and glucose metabolism; and monitoring of prolactin levels, body weight, and blood pressure. If prolactin levels are greater than 100 ng/mL, estrogen therapy should be stopped and prolactin levels should be rechecked after 6 to 8 weeks. If prolactin levels remain high, an MRI scan of the pituitary gland to check for the presence of a prolactinoma should be ordered. Otherwise, estrogen therapy may be restarted at a lower dosage. Cyproterone acetate is particularly associated with elevated prolactin levels, and discontinuation of cyproterone acetate lowers prolactin levels. In contrast to cyproterone acetate, estrogen and spironolactone therapy is not associated with increased prolactin levels.
== External links == The idea of antiangiogenesis was pioneered by Dr. Judah Folkman. See [1] and [2] Angiogenesis Inhibitors for Cancer – from The Angiogenesis Foundation, 23 June 2009 Angiogenesis Inhibitors for Eye Disease – from The Angiogenesis Foundation, 23 June 2009 Angiogenesis Inhibitors in the Treatment of Cancer – from the National Cancer Institute Angiogenesis+Inhibitors at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
== Technique == The technique for dry needling depends on which tissue is being targeted and the overall objective of the treatment. For example, one of the most common treatment objectives for dry needling, myofascial trigger points (TrPs), differs physiologically from treatments for scar tissue, connective tissue problems, and other medical issues. In the treatment of trigger points for persons with myofascial pain syndrome, dry needling is an invasive procedure in which a filiform needle is inserted into the skin and muscle directly at a myofascial trigger point. A myofascial trigger point consists of multiple, hyperirritable contraction knots related to the production and maintenance of the pain cycle; essentially, myofascial trigger points will generate much local pain upon stimulation or irritation. Deep dry needling for treating trigger points was first introduced by the Czech neurologist Karel Lewit in 1979. Lewit had noticed that the success of injections into trigger points in relieving pain was apparently unconnected to the analgesic used. Dry needling can be divided into categories in terms of depth of penetration: deep and superficial dry needling. Deep dry needling will inactivate myofascial trigger points by provoking a local twitch response (LTR), which is an involuntary spinal cord reflex in which the muscle fibers in the taut band of muscle contract. The LTR indicates the proper placement of the needle in a trigger point. Dry needling that elicits LTRs improves treatment outcomes, and may work by activating endogenous opioids.
Strength training exercise is primarily anaerobic. Even while training at a lower intensity (training loads of ≈20-RM), anaerobic glycolysis is still the major source of power, although aerobic metabolism makes a small contribution. Weight training is commonly perceived as anaerobic exercise, because one of the more common goals is to increase strength by lifting heavy weights. Other goals such as rehabilitation, weight loss, body shaping, and bodybuilding often use lower weights, adding aerobic character to the exercise. Except in the extremes, a muscle will fire fibres of both the aerobic or anaerobic types on any given exercise, in varying ratio depending on the load on the intensity of the contraction. This is known as the energy system continuum. At higher loads, the muscle will recruit all muscle fibres possible, both anaerobic ("fast-twitch") and aerobic ("slow-twitch"), to generate the most force. However, at maximum load, the anaerobic processes contract so forcefully that the aerobic fibers are completely shut out, and all work is done by the anaerobic processes. Because the anaerobic muscle fibre uses its fuel faster than the blood and intracellular restorative cycles can resupply it, the maximum number of repetitions is limited. In the aerobic regime, the blood and intracellular processes can maintain a supply of fuel and oxygen, and continual repetition of the motion will not cause the muscle to fail. Circuit weight training is a form of exercise that uses a number of weight training exercise sets separated by short intervals.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.